

Usage Of Biologic & Biosimilar Products

Reference Number: F4899
Date of Response: 29/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] **21 Patients**
- Adalimumab [Humira] **17 Patients**
- Adalimumab Biosimilars **187 Patients**
- Apremilast [Otezla] **6 Patients**
- Baricitinib [Olumiant] **42 Patients**
- Certolizumab [Cimzia] **51 Patients**
- Etanercept [Enbrel] **≤5* Patients**
- Etanercept Biosimilars **89 Patients**
- Filgotinib [Jyseleca] **30 Patients**
- Golimumab [Simponi] **63 Patients**
- Guselkumab [Tremfya] **0 Patients**
- Infliximab [Remicade] **≤5* Patients**
- Infliximab Biosimilars **19 Patients**
- Ixekizumab [Taltz] **13 Patients**
- Risankizumab [Skyrizi] **0 Patients**
- Rituximab [MabThera] **0 Patients**
- Rituximab Biosimilars **33 Patients**
- Sarilumab [Kevzara] **7 Patients**
- Secukinumab [Cosentyx] **28 Patients**
- Tocilizumab [Ro Actemra] **34 Patients**
- Tofacitinib [Xeljanz] **27 Patients**
- Upadacitinib [Rinvoq] **62 Patients**
- Ustekinumab [Stelara] **0 Patients**

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.

- Abatacept [Orencia] **0 Patients**
- Adalimumab [Humira] **≤5* Patients**
- Adalimumab Biosimilars **44 Patients**
- Apremilast [Otezla] **6 Patients**
- Certolizumab [Cimzia] **8 Patients**
- Etanercept [Enbrel] **0 Patients**
- Etanercept Biosimilars **10 Patients**
- Golimumab [Simponi] **25 Patients**
- Guselkumab [Tremfya] **0 Patients**

- Infliximab [Remicade] **0 Patients**
- Infliximab Biosimilars **≤5* Patients**
- Ixekizumab [Taltz] **11 Patients**
- Risankizumab [Skyrizi] **0 Patients**

[*] <5 - In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.